Skip to main content
Fig. 2 | BMC Genomics

Fig. 2

From: MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design

Fig. 2

Predicted HLA-DRB1-binding neo-antigen mutant peptides in 147 lung adenocarcinoma patients. Somatic mutations were predicted by NetMHCIIPan3.1. All patients were lined up according to numbers of HLA-DRB1-binding neo-antigen mutations, including both strong-binders (SB, blue color) and weak-binders (WB, red color). Gray color indicates other mutations which do not bind to MHC Class II molecules. Smokers and non-smokers were analyzed separately

Back to article page